Research Centre
Publications
Peer-reviewed papers, trial reports and academic contributions from Dr. B. S. Chakravarthy and collaborators.
Immunogenicity and safety of a dose-sparing inactivated poliovirus vaccine in infants in India: a phase 2/3, double-blind, randomised controlled trial
The Lancet Infectious Diseases, published online 15 May 2026
This multicentre phase 2/3 trial evaluated an adjuvanted dose-sparing inactivated poliovirus vaccine containing approximately one-fourth the antigen content of standard IPV. The dose-sparing vaccine was non-inferior to full-dose IPV for all three poliovirus serotypes and had a similar safety profile. King George Hospital, Visakhapatnam, was one of the nine participating study centres.
Immunogenicity and safety of Biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p+1 schedule to healthy infants: a multicenter, randomized, active-controlled, single-blind, phase III trial
The Lancet Regional Health – Southeast Asia, 2026; 46: 100746
This phase III trial compared a 14-valent pneumococcal conjugate vaccine (BE-PCV14) with the licensed PCV13 in 400 Indian infants given a 2-dose primary series plus booster. BE-PCV14 produced immune responses comparable to PCV13 across shared serotypes, generated strong responses to its two additional serotypes (22F and 33F), and showed a similar safety profile, supporting its use in routine infant immunization programmes. King George Hospital, Visakhapatnam, was one of seven participating trial sites, with Dr. Chakravarthy as site investigator.
A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority and lot-to-lot consistency of single-component oral cholera vaccine BBV131 (Hillchol®) in comparison to Shanchol™
Vaccine, 2025; 55: 126998
A 1,800-participant phase III trial across ten Indian sites compared Bharat Biotech's single-strain oral cholera vaccine BBV131 (Hillchol®) against the WHO-prequalified Shanchol™ in adults, children and toddlers. BBV131 met non-inferiority criteria for vibriocidal antibody seroconversion against both Ogawa and Inaba serotypes, with a comparable and favourable safety profile across all age groups, supporting its potential as an additional oral cholera vaccine option amid global supply shortages.
Safety and immunogenicity of Biological E’s typhoid conjugate vaccine TYPHIBEV® concomitantly administered with measles rubella vaccine: a phase IV prospective, multicenter study
IJID Regions, 2025; 15: 100611
This phase IV prospective multicentre study enrolled 1,252 healthy participants aged 6 months to 45 years across 11 Indian sites. It evaluated the safety of TYPHIBEV® and assessed whether co-administration with measles-rubella vaccine in infants aged 9–12 months caused immune interference. No new safety signal was identified, and measles and typhoid seroprotection rates were comparable between the co-administration and comparison groups.
A toxico-epidemiological study of pediatric poisoning cases: a retrospective analysis
International Journal of Academic Medicine and Pharmacy, 2026; 8(2): 277–282
A three-year retrospective review of 55 pediatric poisoning admissions at King George Hospital, Visakhapatnam (2022–2024). Toddlers aged 0–3 years were most affected, accidental ingestion accounted for the large majority of cases, and hydrocarbons — particularly thinner oil — were the leading poisoning agent. Early presentation and supportive care resulted in zero mortality, though a subgroup of older children with intentional ingestion and children with pre-existing neurodevelopmental conditions were identified as needing focused prevention strategies.
Accuracy of non-invasive pulse co-oximetry hemoglobin testing compared with laboratory analyzer in pediatric patients: a prospective study at a tertiary care center
International Journal of Academic Medicine and Pharmacy, 2026; 8(2): 524–527
A prospective study of 500 children at Andhra Medical College / King George Hospital comparing non-invasive pulse co-oximetry hemoglobin readings (SpHb) against standard laboratory analysis. SpHb showed moderate overall accuracy for detecting anemia but consistently overestimated hemoglobin at lower levels, with notably reduced sensitivity for moderate and severe anemia. The authors conclude that SpHb is a reasonable bedside screening and trend-monitoring tool, but cannot replace laboratory confirmation when clinical decisions such as transfusion are being considered.
More publications being added
This list is being expanded as further manuscripts are confirmed for publication, including ongoing work from the 4M Kids Trial and the PaedCare KGH research suite. If you are a collaborator and would like a manuscript added or corrected, please reach out via the contact details in the footer.